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Inflammation a b s t r a c t  
Objectives: Cherries are rich in polyphenols and anthocyanins and are believed to possess strong anti-
inflammatory activity and cardio-protective effects. This study aim was to summarize the overall effect 
of sour cherry consumption on blood pressure and biomarkers associated with the inflammation. 
Methods: MEDLINE/PubMed, Cochrane, and Scopus were searched to find relevant papers up to April 
2019. There were no time and language restrictions. This systematic review and meta-analysis was per-
formed in accordance with the Preferred Items for Reporting of Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines. 
Results: Eleven studies with 275 participants were included in this meta-analysis. Mean dose of the sour 
cherry was 170 mL/day, whilst mean duration of interventions was six weeks. Combined the results using 
random-effects model showed significant reductions in diastolic blood pressure levels following sour 
cherry consumption (WMD: 2.32 mmHg, 95% CI: 4.45, 0.19, I2 = 39%), but there were no significant 
changes in systolic blood pressure (WMD: 2.64 mmHg, 95% CI: 5.84, 0.56, I2 = 33%), IL-6 levels (WMD: 
0.12 pg/mL, 95% CI: 0.13, 0.36, I2 = 49%), hs-CRP (WMD: 0.13 mg/mL, 95% CI: 0.47, 0.22, I2 = 49%) or 
TNF-a (WMD: 0.07 pg/mL, 95% CI: 0.18, 0.05, I2 = 00%). 
Conclusion: Sour cherry supplementation results a decrease in diastolic blood pressure, but elicits no sig-
nificant effect on systolic blood pressure, IL-6 levels, CRP levels and TNF-a. 
 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access 
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). , China. 
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Globally, cardiovascular diseases (CVDs) persist as one of the 
primary causes of mortality and morbidity among non-
communicable diseases (Roth et al., 2017). Annually, 17.9 million 
deaths are attributed to CVDs, approximating 31% of the world’s 
deaths. Furthermore, CVDs are estimated to directly cause 80% of 
deaths in Americans who are over 64 years of the age (Benjamin 
et al., 2019), and whilst in 2015, USA health care expenditure for 
CVDs was around 656 billion dollars, it is expected to be double 
by 2030, and reach 1208 billion dollars (Benjamin et al., 2019). 
High blood pressure, or hypertension, and inflammation are the 
two major factors in the development of CVDs and atherosclerosis 
(Gupta et al., 2013). 
Typically, the treatment of high blood pressure and inflamma-
tion consists of medications, primarily consisting of calcium chan-
nel blockers, angiotensin converting enzyme inhibitors, lipid-
lowering agents, diuretics, beta-blockers, and non-steroid anti-
inflammatory drugs (NSAIDs) for inflammation (Chai et al., 2018). 
These medications are shown to be somewhat beneficial in reduc-
ing cardio-vascular risks. Although these agents lower the risk of 
CVDs, they are associated with side effects, such as angiotensin 
converting enzyme inhibitors-induced dry cough, NSAIDs induced 
hepato-toxicity and nephrotoxicity, and lipid-lowering agents 
induced muscle damage(rhabdomyolysis), which cause harm and, 
in some cases, are fatal (Banach et al., 2015). 
Concomitant to traditional pharmacotherapies, there is a grow-
ing evidence base to suggest that natural resources, such as phyto-
chemicals within fruits and vegetables, may act to reduce risk 
CVDs, and conceivably reduce health care burdens (Miller et al., 
2017). However, there is equivocality with regard to whether nat-
ural resources are sufficient to treat and prevent cardiovascular 
risk factors. Indeed, various epidemiological studies state that a 
diet rich in fruits and vegetables serves as a protective agent 
against CVDs. Furthermore, fruits, which are rich, source of 
polyphenolic compounds, especially, anthocyanin, possess poten-
tially cardio-protective properties (Aune et al., 2017). Cherries 
are fruits which are rich in polyphenols and anthocyanin, and are 
believed to possess strong anti-inflammatory activity and cardio-
protective effects. Moreover, cherries increase the activity of nitric 
oxide synthase, which serves to be efficient in arterial stiffness, and 
thus, they may be potentially beneficial in preventing atherosclero-
sis, by helping to maintain proper endothelial functions (Chai et al., 
2018). In addition, cherries possess anti-oxidant properties as well 
as lipid reducing power. Furthermore, there are no known adverse 
side effects associated with cherries, and their consumption can ameliorate post-exercise induced inflammation, improve muscle 
recovery, and enhance circulatory melatonin levels (Lynn et al., 
2014b). Therapeutic application of cherries has also yielded bene-
ficial responses in inflammation-associated diseases, especially in 
osteoarthritis and gout (Schumacher et al., 2013b). A number of 
observational studies exploring the effect of raw cherries on blood 
pressure, C-reactive protein (CRP), Tumor Necrotic Factor (TNF), 
and Interleukin-6 (IL-6) (Chai et al., 2018; Lynn et al., 2014b) have 
recently been conducted, however, to date, there exists no summa-
tive assessment available. Therefore, the aim of the present study 
was to summarize the overall effect of sour cherry consumption 
on blood pressure and the biomarkers associated with 
inflammation. 2. Methods 
PRISMA statement used to conduct present meta-analysis 
(Moher et al., 2015). 2.1. Search strategy 
A search was performed in PubMed/MEDLINE, Cochrane and 
SCOPUS by two reviewers, from database inception until April 
2019. Details of the comprehensive search strategy are presented 
in supplementary Table 1. 2.2. Selection criteria and data extraction 
The PICOS criteria was used to conduct this studies. Two 
authors evaluated the title and abstract of all articles, indepen-
dently. The inclusion criteria for including were: Intervention using 
Sour Cherry, RCT studies reporting our outcome measures in the 
form of mean differences (MD) with the confidence intervals. Stud-
ies that did not report relevant outcomes, were animal-based or 
review studies and non-randomized studies were excluded. Fur-
thermore, studies without a control group, conference, commen-
taries, and case-reports studies were also excluded. 
Data extraction from the included studies as performed by two 
reviewers, independently. 2.3. Quality assessment 
Cochrane tool was used for the assessment of quality of the 
included studies (Higgins et al., 2011). 
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Table 1 
Characteristics of included studies. 
Author Location year Participants (n) Gender(1women, 2men, and 3 both Age (year) dose (mg or ml/ day) Duration of study (week) 
Sheau C. Chai USA 2019 37 3 65–80 480 12 
Brown, M. A. UK 2019 20 2 19 30 1 
Bakkar, Z. A. UK 2019 12 1 54 1.7 4 
Martin, K. R. USA 2018 10 3 38 240 10 
Jackman, S. R. UK 2018 16 1 60–75 30 3 
Desai, T. UK 2018 11 3 30 30 10 
Chai, S. C. USA 2018 37 3 65–80 480 12 
Bell, P. G. UK 2016 16 1 25 30 1 
Levers, K. USA 2015 23 1 20 480 2 
Lynn, A. UK 2014 47 3 30–50 30 6 
Naruszewicz, M. Poland 2007 44 3 56 255 6 2.4. Statistical analysis 
All statistical analyses were conducted using the STATA 14 
(StataCorp LP, College Station, USA). Weighted mean difference 
(WMD) with the 95% CI was used to measure effects of Sour 
Cherry on outcome measures. DerSimonian and Laird method 
random effects model was used to calculate the pooled effects. 
Heterogeneity across the included studies was evaluated by the 
I-squared and an alpha of 0.05 for p heterogeneity. Sensitivity 
analysis was run to examin effect of each studies. The publica-
tion bias evaluated by funnel plot, Egger’s and begg’s weighted 
tests. Fig. 1. Flow chart of 3. Results 
Following comprehensive systematic searching, 63 studies were 
retrieved (Fig. 1). After removing duplicates and title and abstract 
screening, 16 articles remained for full text examination. In full 
text screening, 5 studies were excluded because they did not meet 
our inclusion criteria such as they was not RCTs or was not on 
human, and finally, 11 studies were included in this meta-
analysis(Bakkar et al., 2019; Bell et al., 2016; Brown et al., 2019; 
Chai et al., 2018; Chai et al., 2019a,b; Desai et al., 2018; Jackman 
et al., 2018; Levers et al., 2015; Lynn et al., 2014a; Martin et al., 
2018; Schumacher et al., 2013a). included studies. 
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Table 2 
Risk of bias assessment. 
Study name Year Selection bias Selection bias Performance Detection Attrition bias Reporting bias Other bias 
Random sequence Allocation bias Blinding bias Incomplete Selective Other sources of 
generation concealment Blinding outcome data reporting bias 
Chai, S.C. 2019 Low Unclear Unclear Low Low Low Low 
Brown, M. A. 2019 Low Unclear Low Low Low Low Low 
Bakkar, Z.A 2019 Low Low Low Low Low Low Low 
Martin, K.R. 2018 Low Unclear Low Low Low Low Low 
Jackman S.R. 2018 Low Unclear Low Low unclear Low Low 
Desai, T 2018 Low Unclear Low Low Low Low Low 
Chai, S.C. 2018 Low Unclear Low Low Low Low Low 
Bell, P.G 2016 Low Unclear Low Low Low Low Low 
Levers, K. 2015 Low Unclear Low Low Low Low Low 
Lynn A 2014 Low Low Low Low Low Low Low 
Schumacher, H. 2013 Low Unclear Low Low Low Low Low 3.1. Study characteristics 
Table 1 details characteristics of the included studies, which 
were published between 2013 and 2019 and conducted in the US 
(Chai et al., 2018; Chai et al., 2019a,b; Levers et al., 2015; Martin 
et al., 2018; Schumacher et al., 2013a) or  UK  (Bakkar et al., 2019; 
Bell et al., 2016; Brown et al., 2019; Desai et al., 2018; Jackman 
et al., 2018; Lynn et al., 2014a). The total sample size was 275 par-
ticipants with a men age of 45 years. Mean dose of the sour cherry 
was 170 mL/day, whilst mean duration of interventions was six 
weeks, ranging from one to 12 weeks. The risk of bias in included 
randomized control trials was low (Table 2). 3.2. Results of meta-analysis 
Three studies with 102 participants reported blood pressure as 
an outcome measure (Chai et al., 2018; Desai et al., 2018; Lynn 
et al., 2014a). The random-effects model demonstrated significant 
reductions in diastolic blood pressure levels following sour cherry 
consumption (WMD: 2.32 mmHg, 95% CI: 4.45, 0.19, I2 = 39%) 
(Fig. 1), but there was not any significant change in systolic blood 
pressure (WMD: 2.64 mmHg, 95% CI: 5.84, 0.56, I2 = 33%). 
Three studies, providing 60 participants, reported IL-6 as an 
outcome measure (Bakkar et al., 2019; Jackman et al., 2018; 
Levers et al., 2015). Pooled data showed not reduction in IL-6 levels 
in the intervention group compared with the placebo group 
(WMD: 0.12 pg/mL, 95% CI: 0.13, 0.36, I2 = 49%). 
Results from the random-effects model on seven studies 
(Bakkar et al., 2019; Bell et al., 2016; Brown et al., 2019; Chai 
et al., 2019a,b; Jackman et al., 2018; Lynn et al., 2014a; 
Schumacher et al., 2013a) containing 195 participants (104 partic-
ipants in intervention group and 91 participants in placebo groups) 
indicated that sour cherry did not have significant reduction in hs-
CRP levels (WMD:-0.13 mg/mL, 95% CI: 0.47, 0.22, I2 = 49%) 
(Fig. 2.). 
We analyzed the results from five studies containing 106 partic-
ipants that reported TNF-a as an outcome measures (Bell et al., 
2016; Chai et al., 2019a,b; Jackman et al., 2018; Levers et al., 
2015; Martin et al., 2018) using a random-effects model. The 
results did not show any significant change in the intervention 
group compared to the placebo group (WMD: 0.07 pg/mL, 95% 
CI: 0.18, 0.05,I2 = 00%). 3.3. Publication bias and sensitivity analysis 
Publication bias is illustrated in Supplementary Fig. 1. The 
Egger’s and Begg’s tests show not publication bias for systolic 
blood pressure (p = 0.82, p = 0.60), diastolic blood pressure 
(p = 0.35, p = 0.52), CRP (p = 0.81, p = 0.65), TNF-a (p = 0.31, p = 0.49), and IL-6 (p = 0.27, p = 0.11). The sensitivity analysis 
shows not significant differences beyond the limits of 95% CI of cal-
culated pooled results. 4. Discussion 
Sour cherry is the result of the hybridization of sweet cherry 
and the European dwarf cherry, and belongs to the Rosaceae fam-
ily. Sour cherry (Prunus cerasus L.) is shown to possess anti-oxidant, 
anti-inflammatory and anti-mutagenic activity, which is attributa-
ble to a high flavonoid content. Moreover, sour cherry is considered 
to have the capacity to control hypertension because of the pres-
ence of components like anthocyanins and some flavone and 
flavan-3-ol compounds, although it is difference between hemody-
namic process and inflammatory/oxidative processes (Nemes et al., 
2018; Solak et al., 2016). 
Anthocyanins are natural water-soluble flavonoids, and chemi-
cally they are polydroxy and polymethoxylated glycosides of 
anthocyanidins bound to several moieties. Anthocyanins exhibit 
a wide variety of biological effects, including vasodilators, and 
attributed to act as free radical scavenging and antioxidant activity 
(Soobrattee et al., 2005). However, the major correlation was found 
with vasodilatory capacity (Nile et al., 2015). Evidence from the 
reviews showed that anthocyanins condensed tannin-containing 
fractions that showed to have vasodilation activity compared to 
other polyphenols (Reis et al., 2016). In a rat model study, hyper-
tensive stroke-prone rats are treated with anthocyanins rich blue-
berries for 8 weeks demonstrated significant reduction in the 
systolic blood pressure. Anthocyanins showed nitric oxide-
dependent vasodilation via endothelium induced by acetylcholine 
through the nitric oxide metabolism pathway — furthermore, the 
other vasodilator effect of anthocyanins in the endothelium-
dependent relaxation (Kalea et al., 2009). 
Clinical trials have yielded evidence that sour cherry can signif-
icantly reduce hypertension, were such effects are likely manifest 
due to the circulating phenolic content of the cherries (Keane 
et al., 2016). Moreover, Chai et al. suggested that the anti-
hypertensive ability of sour cherry can be due to its anti-oxidant 
and anti-inflammatory activity (Chai et al., 2019a,b). 
We analyzed eleven studies and found that sour cherry con-
sumption can significantly reduce diastolic blood pressure, but eli-
cited no significant effect on systolic blood pressure, IL-1 levels, hs-
CRP levels, and TNF-a. We observed that sour cherry consumption 
can significantly reduce diastolic blood pressure but the reduction 
in the systolic blood pressure, was found to be non-significant. 
Sour cherry has a high flavonoid content (Nemes et al., 2018), 
which are well linked with the prevention of CVDs (He & Giusti, 
2010). Moreover, a previous meta-analysis of seven prospective 
cohort studies revealed that flavonol intake can significantly 
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Fig. 2. Meta-analysis of effect of Sour Cherry on (a) Systolic blood pressure, (b) Diastolic blood pressure, (c) CRP, (d) TNF, and (e) IL-1. reduce the cardiovascular mortality risk (Huxley & Neil, 2003), 
whilst a significant reduction in blood pressure, HbA1c and body 
weight was observed among diabetic woman (Ataie-Jafari et al., 
2008). However, our study revealed that there is no significant 
reduction in systolic BP, which has previously been reported 
(Anthony Lynn et al., 2014). Thus, there is a need to assess the 
exact chemical constituency of sour cherries, to ascertain what is 
contributing to its cardioprotective effect. However, evidence from 
seven studies included in the present meta-analysis demonstrated 
that there was no significant reduction in CRP level after consump-
tion of sour cherry, when compared to the placebo group. CRP can 
inhibit nitric oxide (NO) production and bioavailability, which, in 
turn, leads to the process of inflammation, atherogenesis and scle-rosis (Chai et al., 2019a,b). CRP is strongly recommended as an 
inflammatory response mediator, and a rise in CRP level can indi-
cate an increased cardiovascular risk (Willerson & Ridker, 2004). 
Previously, it has been reported that patients who have low CRP 
levels have better clinical outcomes than those with higher CRP 
levels, and a 75% higher risk in those in the highest quartile of 
CRP,when compared to those who are in the lowest quartile range 
of CRP (Ridker et al., 1998). However, our analysis revealed that 
sour cherry consumption did not reduce the levels of CRP, and thus, 
may not represent a viable strategy in reducing CRP levels. 
In the present study, pooled analysis of studies revealed that 
sour cherry juice consumption was not significantly associated 
with IL-6 and TNF-a reduction, when compared to the placebo 
1692 B. Han et al. / Journal of King Saud University – Science 32 (2020) 1687–1693 group. It is evident that an increase in IL-1b and IL-18 levels will be 
observed in cases of hypertension, and subsequently lead to renal 
and vascular inflammation (Krishnan et al., 2014). TNF-a and IL-1b 
are heavily involved in the pathogenesis of inflammatory bowel 
disease, and empirical studies have shown that anthocyanin 
extract of pure sour cherry can significantly reduce the production 
of TNF-a and IL-1b. Moreover, sour cherry extract can significantly 
inhibit the production of IL-6 and IL-8, and shown to be beneficial 
in controlling inflammatory bowel disease monolayers (Le Phuong 
Nguyen et al., 2018). 
A recent review by Ahmed et al. highlighted that sour cherries 
are widely used in the Unani and Ayurvedic system of medicine, 
and it is quoted as essential in the treatment of urinary tract infec-
tions and other urinary diseases. Furthermore, Amhed et al 
asserted that sour cherry contains heptatonic, lithotriptic, diuretic, 
antipyretic, astringent, detergent, demulcent, spermatogenic, 
aphrodisiac, brain-tonic, anti-inflammatory, sedative and antioxi-
dant properties (Shamsi, 2017). Constituents, like cyanidin-3-
glucosyl-rutinoside and cyanidin-3-rutinoside, have been shown 
to exhibit an anti-oxidant and anti-inflammatory effect, which 
can be attributed to the cardioprotective effect of the sour cherry 
fruit and its byproducts (Yılmaz et al., 2018). 
The strength of the current meta-analysis that we have used the 
highest level of evidence available, randomized controlled trials, to 
assess the effect of sour cherry on hypertension and inflammatory 
biomarkers, whilst there was no heterogeneity observed among all 
the studies. However, there was some limitation to the study. Even 
though we have performed a comprehensive electronic database 
literature search, we elected to omit grey literature, which may 
conceivably contain some relevant findings. 
5. Conclusion 
Sour cherry decrease diastolic blood pressure, but elicits no sig-
nificant effect on systolic blood pressure, IL-6 levels, hs-CRP levels 
and TNF-a. Although, results show reducing effect of cherry but 
use from it in practice dependent to individual and country price 
and conditions. 
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